<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sufentanil: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sufentanil: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sufentanil: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9954" href="/d/html/9954.html" rel="external">see "Sufentanil: Drug information"</a> and <a class="drug drug_patient" data-topicid="11429" href="/d/html/11429.html" rel="external">see "Sufentanil: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F58073991"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">FDA Requiring Updates to Opioid Prescribing Information</span>
<span class="collapsible-date">April 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">The FDA has issued a drug safety communication to announce safety-related updates to the prescribing information for immediate-release (IR) and extended-release (ER)/long-acting (LA) opioid analgesics, including updates to Boxed Warnings, Indications and Usage, Dosage and Administration, Warnings and Precautions, and the Medication Guide. These safety labeling changes are intended to provide clarity on appropriate patient populations for opioid treatment, appropriate dosage and administration, and updated information on the risks associated with opioid use. The required safety labeling changes include stating:</p>
<ul>
<li>
<p style="text-indent:0em;">the risk of overdose increases as the dosage increases for all opioid pain medicines;</p></li>
<li>
<p style="text-indent:0em;">IR opioids should not be used for an extended period of time unless a patient's pain remains severe enough to require them and alternative treatment options continue to be inadequate;</p></li>
<li>
<p style="text-indent:0em;">many acute pain conditions treated in the outpatient setting require no more than a few days of an opioid pain medicine;</p></li>
<li>
<p style="text-indent:0em;">it is recommended to reserve ER/LA opioid pain medicines for severe and persistent pain that requires an extended treatment period with a daily opioid pain medicine and for which alternative treatment options are inadequate; and</p></li>
<li>
<p style="text-indent:0em;">a warning about opioid-induced hyperalgesia (OIH), including information on differentiating OIH symptoms from those of opioid tolerance and withdrawal.</p></li></ul>
<p style="text-indent:0em;">Further information may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use&amp;token=W5X7myh%2Fi%2FQGr76L%2FoSZbu%2BwYKvRHJDB8O4e79tNg%2FJelrlNqz4gv2DJCwSZVkI3gE10g96a4t1z3Z59rSO%2Fb6izsjmacse6U4o7Ho29jYziQVHf0MYzW7j8%2B8LrQ2%2B4Ru4vvCtWrdS3FrWL%2B0kz4ajIBlnws%2B6VB3AxZWaliq8%3D&amp;TOPIC_ID=12812" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F49447368"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Accidental exposure and Risk Evaluation and Mitigation Strategy (REMS) program (sublingual tablet):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Accidental exposure to or ingestion of sufentanil, especially in children, can result in respiratory depression and death. Because of the potential for life-threatening respiratory depression due to accidental exposure, sufentanil is only available through a restricted program called the Dsuvia REMS Program. Sufentanil must only be dispensed to patients in a certified medically supervised health care setting. Discontinue use of sufentanil prior to discharge or transfer from the certified medically supervised health care setting.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Life-threatening respiratory depression:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious, life-threatening, or fatal respiratory depression may occur with use of sufentanil, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of sufentanil are essential.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Addiction, abuse, and misuse:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Because the use of sufentanil exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing sufentanil, and reassess all patients regularly for the development of these behaviors and conditions.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cytochrome P450 3A4 interaction:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The concomitant use of sufentanil with all cytochrome P450 3A4 inhibitors may result in an increase in sufentanil plasma concentrations, which could increase or prolong adverse drug reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in sufentanil plasma concentration. Monitor patients receiving sufentanil and any CYP3A4 inhibitor or inducer.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risks from concomitant use with benzodiazepines or other CNS depressants:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of sufentanil and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F52679104"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Dsuvia</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1055535"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Analgesic, Opioid</span>;</li>
<li>
<span class="list-set-name">General Anesthetic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462600"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Doses should be titrated to appropriate effects; wide range of doses, dependent upon desired degree of analgesia or anesthesia. Should only be administered under the supervision of a qualified physician experienced in the use of anesthetics.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e3f5d39-cd40-4b93-9738-aad28652895d">Analgesia/sedation in mechanically ventilated patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Analgesia/sedation in mechanically ventilated patients</b>: Limited data available: Preterm neonates: IV: Loading dose: 0.5 mcg/kg/dose administered over 10 minutes, followed by 0.2 mcg/kg/<b>hour</b> continuous infusion was used in 15 mechanically ventilated premature neonates (mean GA: 29.1 weeks (26 to 34 weeks) and produced "burst-suppression-like" EEG patterns (Nguyen The Tich 2003)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1158892f-c996-488b-9ede-bed586df8de9">General anesthesia, adjunct</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>General anesthesia, adjunct (deep intraoperative anesthesia for neonatal cardiac surgery):</b> Limited data available: Full-term neonate: IV: 5 to 10 mcg/kg/dose as needed; followed by a continuous IV infusion (for postoperative anesthesia): 2 mcg/kg/<b>hour</b> for 24 hours (Anand 1992)</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F223621"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Doses should be titrated to appropriate effects; wide range of doses, dependent upon patient age (particularly young infants), desired degree of analgesia or anesthesia; use lean body weight to dose patients who are &gt;20% above ideal body weight. Should only be administered under the supervision of a qualified physician experienced in the use of anesthetics.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f95d04ca-758c-4fcb-8864-fad2d283bb0a">Cardiac surgery anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac surgery anesthesia:</b> Infants, Children, and Adolescents: IV: Initial: 5 to 25 mcg/<b>kg</b>; repeat maintenance doses: 1 to 5 mcg/<b>kg</b>/doses up to 25 to 50 mcg/dose as needed based on response to initial dose and as determined by changes in vital signs indicating surgical stress or lightening of anesthesia; data based on experience in cardiac surgery, which requires much higher induction and maintenance doses; lower dosing may be sufficient for other procedures (Coté 2013; Moore 1985).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="51343076-814c-43b0-b411-64b3e2d636da">Epidural</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Epidural:</b> Limited data available: Infants ≥3 months and Children: Epidural (preservative free) injection: Initial bolus: 0.2 mcg/kg followed by continuous infusion at 0.1 mcg/kg/hour in combination with ropivacaine (Woloszczuk-Gebicka 2014).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="08e87b36-08df-4d6d-bc69-f4531114dc95">Sedation, preoperative or procedural</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation, preoperative or procedural:</b> Limited data available: Children ≥3 years: Intranasal (using parenteral preparation): 1 to 3 mcg/kg in combination with other agents (Bayrak 2007; Coté 2013; Henderson 1988; Hitt 2014; Lundeberg 2011; Roelofse 2004).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51160201"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution and reduce dose as needed; titrate slowly and closely monitor for signs of CNS and respiratory depression. A case-series evaluation of six pediatric patients (age range: 10 to 15 years) with chronic renal failure undergoing transplantation did not show overall differences in pharmacokinetic parameters compared to normal renal function; however, amongst the pediatric patients, a high degree of variability was observed; dosing should be individualized (Davis 1988)</p></div>
<div class="block dohp drugH1Div" id="F51160202"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution and reduce dose as needed; titrate slowly and closely monitor for signs of CNS and respiratory depression.</p></div>
<div class="block doa drugH1Div" id="F223609"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9954" href="/d/html/9954.html" rel="external">see "Sufentanil: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing should be individualized based on patient-specific factors (eg, comorbidities, severity of pain, degree of opioid experience/tolerance) and titrated to patient-specific treatment goals (eg, improvement in function and quality of life, decrease in pain using a validated pain rating scale). Use the lowest effective dose for the shortest period of time.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Opioids may be part of a comprehensive, multimodal, patient-specific treatment plan for managing moderate to severe pain. Maximize nonopioid analgesia (when appropriate) prior to initiation of opioid analgesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327391','lexi-content-ref-28267689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327391','lexi-content-ref-28267689'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4cb8e7f4-6ca1-47b8-80b7-8e571212d9dd">Acute pain management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute pain management:</b> Sublingual tablet: Initial: Sublingual: 30 mcg; may repeat as needed with a minimum of 1 hour between doses; maximum dose: 360 mcg/day (12 tablets); do not use for &gt;72 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Only administer in a certified medically supervised health care setting by a health care provider; discontinue treatment prior to discharge from supervised setting.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58f8fe80-ca99-45e3-a469-dc9a9f3debc9">Surgical analgesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical analgesia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Surgical analgesia (as a component of balanced anesthesia) (surgery expected to last: 1 to 2 hours):</b> IV: Total dose: 1 to 2 mcg/kg with N<sub>2</sub>O/O<sub>2</sub>; ≥75% of total dose may be administered by slow injection or infusion prior to intubation (titrate to individual response).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Incremental dosing: According to the manufacturer, 10 to 25 mcg may be administered as needed when movement and/or changes in vital signs indicate surgical stress or lightening of analgesia. May also administer doses in the range of 5 to 20 mcg as needed (Barash 2009) <b>or</b> 0.1 to 0.25 mcg/<b>kg</b> as needed (Miller 2010). Total dose should not exceed 1 mcg/kg/hour of expected surgical time.</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous infusion: May also be administered as a continuous infusion with the infusion rate based on the induction dose used. Maximum infusion rate according to the manufacturer: 1 mcg/kg/hour. May also administer doses in the range of 0.3 to 0.9 mcg/kg/hour (Barash 2009) <b>or</b> 0.5 to 1.5 mcg/kg/hour (Miller 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Surgical analgesia (as a component of balanced anesthesia) (surgery expected to last 2 to 8 hours):</b> Total dose: 2 to 8 mcg/kg with N<sub>2</sub>O/O<sub>2</sub>; ≤75% of total dose may be administered by slow injection or infusion prior to intubation (titrate to individual response).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Incremental dosing: According to the manufacturer, 10 to 50 mcg may be administered as needed when movement and/or changes in vital signs indicate surgical stress or lightening of analgesia. Total dose should not exceed 1 mcg/kg/hour of expected surgical time.</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous infusion: May also be administered as a continuous infusion with the infusion rate based on the induction dose used. Maximum infusion rate according to the manufacturer: 1 mcg/kg/hour. May also administer doses in the range of 0.3 to 0.9 mcg/kg/hour (Barash, 2009) <b>or</b> 0.5 to 1.5 mcg/kg/hour (Miller, 2010).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="013a59a6-59f6-46ae-a85d-0d3afe29184e">Surgical anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical anesthesia:</b> Total dose: 8 to 30 mcg/kg as a slow injection, infusion, or injection followed by infusion; titrate to individual patient response. <b>Note:</b> In patients administered high doses of sufentanil, qualified personnel and adequate facilities are necessary to manage the potential for postoperative respiratory depression.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Incremental dosing: 0.5 to 10 mcg/kg as needed in anticipation of surgical stress</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous infusion: Base infusion rate on the induction dose so that the total dose for the procedure does not exceed 30 mcg/kg</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f0caeed2-1494-451b-80b4-9c890670c73c">Analgesia for labor and delivery</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Analgesia for labor and delivery:</b> Epidural: 10 to 15 mcg with bupivacaine 0.125% with/without epinephrine. Dose can be repeated twice (for a total of 3 doses) at not less than 1-hour intervals until delivery.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991439"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution and reduce dose as needed; titrate slowly and closely monitor for signs of CNS and respiratory depression.</p></div>
<div class="block doha drugH1Div" id="F50988733"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution and reduce dose as needed; titrate slowly and closely monitor for signs of CNS and respiratory depression.</p></div>
<div class="block adr drugH1Div" id="F223584"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (epidural administration with bupivacaine: 25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, ECG abnormality, flushing, hypertension, orthostatic hypotension, peripheral vasodilation, presyncope, sinus tachycardia, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention, abdominal distress, constipation, decreased gastrointestinal motility, diarrhea, dyspepsia, eructation, flatulence, gastritis, hiccups, intestinal obstruction (postoperative), oral hypoesthesia, retching, upper abdominal pain, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Decreased urine output, oliguria, urinary hesitancy, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, anxiety, confusion, disorientation, drowsiness, drug abuse, drug dependence, euphoria, hallucination, hemiparesis, insomnia, lethargy, memory impairment, mental status changes, sedated state</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle rigidity, muscle spasm</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Miosis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Kidney failure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, atelectasis, bradypnea, hypoventilation, hypoxia, oxygen saturation decreased, respiratory depression, respiratory distress, respiratory failure</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Allodynia (opioid-induced hyperalgesia) (FDA Safety Communication 2023)</p></div>
<div class="block coi drugH1Div" id="F223597"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis) to sufentanil or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">Additional contraindications for sublingual tablets: Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to fentanyl or other morphinomimetics; IV use during labor or before clamping cord during cesarean section; epidural administration in patients with severe hemorrhage or shock, septicemia, or infection at proposed puncture site</p></div>
<div class="block war drugH1Div" id="F223581"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease. Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis (Brennan 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bradyarrhythmias: Severe bradycardia may occur; use with caution in patients with bradyarrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperalgesia: Opioid-induced hyperalgesia (OIH) has occurred with short-term and prolonged use of opioid analgesics. Symptoms may include increased levels of pain upon opioid dosage increase, decreased levels of pain upon opioid dosage decrease, or pain from ordinarily nonpainful stimuli; symptoms may be suggestive of OIH if there is no evidence of underlying disease progression, opioid tolerance, opioid withdrawal, or addictive behavior. Consider decreasing the current opioid dose or opioid rotation in patients who experience OIH.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute myocardial infarction), or drugs that may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Use injection with caution in patients with circulatory shock. Avoid use of sublingual tablets in patients with circulatory shock.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory depression: Fatal respiratory depression may occur. Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. Patients and caregivers should be educated on how to recognize respiratory depression and the importance of getting emergency assistance immediately (eg, calling 911) in the event of known or suspected overdose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with concomitant use of sufentanil and serotonergic agents (eg, selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, 5-HT receptor antagonists, mirtazapine, trazodone, tramadol) and agents that impair metabolism of serotonin (eg, monoamine oxidase inhibitors). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile BP, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue sufentanil if serotonin syndrome is suspected.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions. Use of sublingual tablets is contraindicated with known or suspected GI obstruction, including paralytic ileus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Biliary tract impairment: Use with caution in patients with biliary tract dysfunction, including acute pancreatitis; opioids may cause constriction of sphincter of Oddi.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression/coma: Use with caution in patients with impaired consciousness or coma as these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Delirium tremens: Use opioids with caution in patients with delirium tremens.</p>
<p style="text-indent:-2em;margin-left:4em;">• Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution and reduce dose as needed in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Obesity: Use with caution in patients who are morbidly obese. Consider use of lean body weight for dosing in patients &gt;20% over ideal body weight.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary stricture: Use opioids with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychosis: Use opioids with caution in patients with toxic psychosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution and reduce dose as needed in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression, particularly when initiating and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients with a history of seizure disorders; may increase risk or exacerbate preexisting seizure disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep-related disorders: Use with caution in patients with sleep-related disorders, including sleep apnea, due to increased risk for respiratory and CNS depression. Monitor carefully and titrate dosage cautiously in patients with mild sleep-disordered breathing. Avoid opioids in patients with moderate to severe sleep-disordered breathing (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Use opioids with caution in patients with thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in hypotension, profound sedation, respiratory depression, coma, and death. Following the administration of sufentanil, the dose of other CNS depressant drugs should be reduced. Consider prescribing naloxone for emergency treatment of opioid overdose in patients taking benzodiazepines or other CNS depressants concomitantly with opioids.</p>
<p style="text-indent:-2em;margin-left:4em;">• CYP3A4 interactions: Use with all CYP3A4 inhibitors may result in an increase in sufentanil plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitant CYP3A4 inducer may result in increased sufentanil concentrations. Monitor patients receiving sufentanil and any CYP3A4 inhibitor or inducer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use opioids with caution in older adults; may be more sensitive to adverse effects. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increased adverse effects. Monitor closely for adverse effects associated with opioid therapy (eg, respiratory and CNS depression, falls, cognitive impairment, constipation) (CDC [Dowell 2022]). Consider the use of alternative nonopioid analgesics in these patients when possible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates: Neonatal opioid withdrawal syndrome: Signs and symptoms include irritability, hyperactivity, and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. Onset, duration, and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use caution in neonates as clearance of sufentanil is much slower than adults; neonates with cardiovascular disease have an even slower clearance. The clearance of sufentanil in children 2 to 8 years of age was shown to be twice as rapid as that seen in adults and adolescents (Lundeberg 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse/misuse/diversion: Use with caution in patients with a history of substance abuse disorder; potential for drug dependency exists. Other factors associated with increased risk for misuse include concomitant depression or other mental health conditions, higher opioid dosages, or taking other CNS depressants. Consider offering naloxone prescriptions in patients with an increased risk for overdose, such as history of overdose or substance use disorder, higher opioid dosages (≥50 morphine milligram equivalents/day orally), concomitant benzodiazepine use, and patients at risk for returning to a high dose after losing tolerance (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Accidental exposure (sublingual tablet): Accidental exposure to or ingestion of sufentanil, especially in children, can result in respiratory depression and death.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Epidural: Proper placement of the needle or catheter in the epidural space should be verified before injection to assure that unintentional intravascular or intrathecal administration does not occur. Unintentional intravascular injection may result in a potentially serious overdose, including acute truncal muscular rigidity and apnea. Unintentional intrathecal injection of the full sufentanil/bupivacaine epidural doses and volume may produce effects of high spinal anesthesia, including prolonged paralysis and delayed recovery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Naloxone access: Discuss the availability of naloxone with all patients who are prescribed opioid analgesics, as well as their caregivers, and consider prescribing it to patients who are at increased risk of opioid overdose. These include patients who are also taking benzodiazepines or other CNS depressants, have an opioid use disorder (OUD) (current or history of), or have experienced opioid-induced respiratory depression/opioid overdose. Additionally, health care providers should consider prescribing naloxone to patients prescribed medications to treat OUD; patients at risk of opioid overdose even if they are not taking an opioid analgesic or medication to treat OUD; and patients taking opioids, including methadone or buprenorphine for OUD, if they have household members, including children, or other close contacts at risk for accidental ingestion or opioid overdose. Inform patients and caregivers on options for obtaining naloxone (eg, by prescription, directly from a pharmacist, a community-based program) as permitted by state dispensing and prescribing guidelines. Educate patients and caregivers on how to recognize respiratory depression, proper administration of naloxone, and getting emergency help (FDA 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• Rapid infusion: Injection: Inject slowly over at least 2 minutes (Sebel 1982); rapid IV infusion may result in skeletal muscle and chest wall rigidity, impaired ventilation, or respiratory distress/arrest; nondepolarizing skeletal muscle relaxant may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• REMS program (sublingual tablet): Because of the potential for life-threatening respiratory depression due to accidental exposure, sufentanil is only available through a restricted program called the REMS Program. Sufentanil must only be dispensed to patients in a certified medically supervised health care setting. Discontinue use of sufentanil prior to discharge or transfer from the certified medically supervised health care setting. Information about the REMS program is available by calling 1-855-925-8476 or at www.DSUVIAREMS.com.</p>
<p style="text-indent:-2em;margin-left:4em;">• Trained individuals: Injection: Sufentanil should be administered by health care providers specifically trained in the use of anesthetic agents and should not be used in diagnostic or therapeutic procedures outside the monitored anesthesia setting; resuscitative and intubation equipment should be readily available.</p></div>
<div class="block foc drugH1Div" id="F223591"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mcg/mL (1 mL); 100 mcg/2 mL (2 mL); 250 mcg/5 mL (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Sublingual, Sublingual, as citrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dsuvia: 30 mcg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p></div>
<div class="block geq drugH1Div" id="F223577"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323903"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (SUFentanil Citrate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mcg/mL (per mL): $5.87 - $8.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg/2 mL (per mL): $4.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mcg/5 mL (per mL): $3.48</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Sublingual</b> (Dsuvia Sublingual)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mcg (per each): $96.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868307"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mcg/mL (1 mL, 5 mL)</p></div>
<div class="block csi drugH1Div" id="F223637"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-II</p></div>
<div class="block admp drugH1Div" id="F52613886"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Administer at a concentration ≤ 50 mcg/mL (undiluted)</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV: May be administered by either slow injection or as an infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Slow IV injection: Administer over at least 2 minutes (Moore 1985; Sebel 1982); in adults, a range of 2 to 10 minutes has been used (Miller 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Administer as a continuous infusion via an infusion pump</p>
<p style="text-indent:-2em;margin-left:2em;">Intranasal: Administer using a needleless syringe over 15 to 20 seconds (Henderson 1988) or by a nasal actuating device (eg, GoMedical Nasal Device or MAD nasal drug delivery device) (Hitt 2014; Roelofse 2004)</p></div>
<div class="block adm drugH1Div" id="F25049971"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Intermittent doses may be administered IV as either a slow injection (eg, over at least 2 minutes [Sebel 1982] or a range of 2 to 10 minutes [Miller 2010]) or as an infusion. May also be administered as a continuous infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Sublingual tablet: Administer by a health care provider in a certified medically supervised health care setting only. Wear gloves when administering. Tablet is packaged in a single-dose applicator; do not open until ready to administer. Patient should open their mouth and touch their tongue to roof of mouth. Using the single-dose applicator, administer into sublingual space. Patient should not chew or swallow tablet; do not eat or drink and minimize talking for 10 minutes after administration. Refer to manufacturer’s labeling for additional information.</p></div>
<div class="block sts drugH1Div" id="F25049778"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store at 20°C to 25°C (68°F to 77°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Sublingual tablet: Store at 20°C to 25°C (68°F to 77°F); excursions permitted at 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53568953"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Primary anesthetic agent for the induction and maintenance of anesthesia with 100% oxygen in patients undergoing major surgical procedures; analgesic adjunct for the maintenance of balanced general anesthesia in patients who are intubated and ventilated; in patients who are intubated and ventilated, such as cardiovascular surgery or neurosurgical procedures in the sitting position, to provide favorable myocardial and cerebral oxygen balance or when extended postoperative ventilation is anticipated (All indications: FDA approved in pediatric patients [age not specified] and adults); has also been used intranasally for preprocedural sedation.</p>
<p style="text-indent:-2em;margin-left:2em;">Epidural: Analgesic combined with low-dose bupivacaine during labor and vaginal delivery (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Sublingual tablet: Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate (Dsuvia: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F223644"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">SUFentanil may be confused with ALfentanil, fentaNYL</p>
<p style="text-indent:-2em;margin-left:4em;">Sufenta may be confused with Alfenta, Sudafed, Survanta</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F223631"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F223586"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alvimopan: Opioid Agonists may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the analgesic effect of Opioid Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of SUFentanil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of SUFentanil. Management: If a strong CYP3A4 inducer is initiated in a patient on sufentanil, consider a sufentanil dose increase and monitor for decreased sufentanil effects and opioid withdrawal symptoms.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of SUFentanil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of SUFentanil. Management: If a strong CYP3A4 inhibitor is initiated in a patient on sufentanil, consider a sufentanil dose reduction and monitor for increased sufentanil effects and toxicities (eg, respiratory depression).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Opioid Agonists may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diuretics: Opioid Agonists may enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Opioid Agonists may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Opioid Agonists may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: SUFentanil may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the risk for serotonin syndrome or opioid toxicities (eg, respiratory depression, coma) may be increased.  Management: Sufentanil should not be used with monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) due to the potential for serotonin syndrome and/or excessive CNS depression.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalfurafine: Opioid Agonists may enhance the adverse/toxic effect of Nalfurafine. Opioid Agonists may diminish the therapeutic effect of Nalfurafine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalmefene: May diminish the therapeutic effect of Opioid Agonists. Management: Avoid the concomitant use of oral nalmefene and opioid agonists. Discontinue oral nalmefene 1 week prior to any anticipated use of opioid agonists. If combined, larger doses of opioid agonists will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naltrexone: May diminish the therapeutic effect of Opioid Agonists. Management: Seek therapeutic alternatives to opioids. See full drug interaction monograph for detailed recommendations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: Opioid Agonists (metabolized by CYP3A4) may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. Nefazodone may increase the serum concentration of Opioid Agonists (metabolized by CYP3A4).  Management: If concomitant use of opioid agonists that are metabolized by CYP3A4 and nefazodone is necessary, consider dose reduction of the opioid until stable drug effects are achieved. Monitor for increased opioid effects and serotonin syndrome/serotonin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Agonists. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: Opioid Agonists may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May enhance the CNS depressant effect of SUFentanil. PHENobarbital may decrease the serum concentration of SUFentanil. Management: Avoid use of sufentanil and phenobarbital when possible. Monitor for respiratory depression/sedation. Because phenobarbital is also a strong CYP3A4 inducer, monitor for decreased sufentanil efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May enhance the CNS depressant effect of SUFentanil. Primidone may decrease the serum concentration of SUFentanil. Management: Avoid use of sufentanil and primidone when possible. Monitor for respiratory depression/sedation. Because primidone is also a strong CYP3A4 inducer, monitor for decreased sufentanil efficacy and withdrawal if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Opioid Agonists may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: May diminish the therapeutic effect of Opioid Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Opioid Agonists (metabolized by CYP3A4) may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Somatostatin Analogs: Opioid Agonists may diminish the analgesic effect of Somatostatin Analogs. Opioid Agonists may enhance the analgesic effect of Somatostatin Analogs. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: May enhance the bradycardic effect of Opioid Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52615036"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Chronic opioid use may cause hypogonadism and hyperprolactinemia, which may decrease fertility in patients of reproductive potential. Menstrual cycle disorders (including amenorrhea), erectile dysfunction, and impotence have been reported. The incidence of hypogonadism may be increased with the use of opioids in high doses or long-acting opioid formulations. It is not known if the effects on fertility are reversible. Monitor patients on long-term therapy (de Vries 2020; Gadelha 2022). Sufentanil is not indicated for chronic use.</p></div>
<div class="block pri drugH1Div" id="F5050046"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Sufentanil crosses the placenta (Cuypers 1995; Loftus 1995).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal use of opioids may be associated with poor fetal growth, stillbirth, and preterm delivery (CDC [Dowell 2022]). Opioids used as part of obstetric analgesia/anesthesia during labor and delivery may temporarily affect the fetal heart rate (ACOG 2019b).</p>
<p style="text-indent:0em;margin-top:2em;">Neonatal abstinence syndrome (NAS)/neonatal opioid withdrawal syndrome (NOWS) may occur following prolonged in utero exposure to opioids (CDC [Dowell 2022]). NAS/NOWS may be life-threatening if not recognized and treated and requires management according to protocols developed by neonatology experts. Presentation of symptoms varies by opioid characteristics (eg, immediate release, sustained release), time of last dose prior to delivery, drug metabolism (maternal, placental, and infant), net placental transfer, as well as other factors (AAP [Hudak 2012]; AAP [Patrick 2020]). Clinical signs characteristic of withdrawal following in utero opioid exposure include excessive crying or easily irritable, fragmented sleep (&lt;2 to 3 hours after feeding), tremors, increased muscle tone, or GI dysfunction (hyperphagia, poor feeding, feeding intolerance, watery or loose stools) (Jilani 2022). NAS/NOWS occurs following chronic opioid exposure and would not be expected following the use of opioids at delivery (AAP [Patrick 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Monitor infants of mothers on long-term/chronic opioid therapy for symptoms of withdrawal. Symptom onset reflects the half-life of the opioid used. Monitor infants for at least 3 days following exposure to immediate-release opioids; monitor for at least 4 to 7 days following exposure to sustained-release opioids (AAP [Patrick 2020]; CDC [Dowell 2022]). Monitor newborns for excess sedation and respiratory depression when opioids are used during labor.</p>
<p style="text-indent:0em;margin-top:2em;">When opioids are needed to treat acute pain in pregnant patients, the lowest effective dose for only the expected duration of pain should be prescribed (CDC [Dowell 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Sufentanil injection is commonly used to treat maternal pain during labor and immediately postpartum (ACOG 2019b). Administration of epidural sufentanil with bupivacaine with or without epinephrine is indicated for use in labor and delivery. Sufentanil tablets are not recommended for use during or immediately before labor. Opioid use for pain following vaginal or cesarean delivery should be made as part of a shared decision-making process. A stepwise multimodal approach to managing postpartum pain is recommended. A low-dose, low-potency, short-acting opioid can be used to treat acute pain associated with delivery when needed (ACOG 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Opioids are not preferred for the treatment of chronic noncancer pain during pregnancy; consider strategies to minimize or avoid opioid use (ACOG 2017; CDC [Dowell 2022]). Sufentanil is not indicated for chronic use.</p>
<p style="text-indent:0em;margin-top:2em;">Sufentanil injection is approved for use in surgical procedures. Pregnant patients should not be denied medically necessary surgery, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 2019a).</p></div>
<div class="block mopp drugH1Div" id="F53568952"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Respiratory rate, blood pressure, heart rate, oxygen saturation, neurological status (for degree of analgesia/anesthesia)</p></div>
<div class="block pha drugH1Div" id="F223580"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds to opioid receptors throughout the CNS. Once receptor binding occurs, effects are exerted by opening K+ channels and inhibiting Ca++ channels. These mechanisms increase pain threshold, alter pain perception, inhibit ascending pain pathways; short-acting opioid; dose-related inhibition of catecholamine release (up to 30 mcg/kg) controls sympathetic response to surgical stress.</p></div>
<div class="block phk drugH1Div" id="F223596"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Analgesia: IV: 1 to 3 minutes; Epidural: 10 minutes; Sublingual tablets: ~30 minutes (Fisher 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Dose dependent: Anesthesia adjunct doses:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Context-sensitive half-time and recovery varies depending on dose, duration of administration, concomitant anesthesia, and other clinical factors (Miller 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Epidural: 10 to 15 mcg with bupivacaine 0.125%: 1.7 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual tablets: ~3 hours (Fisher 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: Children 2 to 8 years of age: 2.9 ± 0.6 L/kg; Adults: 1.7 ± 0.2 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Neonates: 79%; Adults: 91% to 93%; primarily to alpha 1-acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic and small intestine via demethylation and dealkylation.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Sublingual tablet: ~53%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Neonates: 7.2 ± 2.7 hours; Infants and Children (2 to 8 years of age): 97 ± 42 minutes; Adolescents 10 to 15 years of age: 76 ± 33 minutes; Adults: 164 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Sublingual tablet: 2.5 ± 0.85 hours (Fisher 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Sublingual tablet: 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (2% excreted as unchanged drug; 80% metabolites) within 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 8 years: 30.5 ± 8.8 mL/minute/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: 12.8 ± 12 mL/minute/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 12.7 ± 0.8 mL/minute/kg.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F223600"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Sufenta | Sufentanil Actavis | Sufentanil hameln | Sufentanil nycomed | Sufentanil torrex pharma | Zalviso</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dzuveo | Sufentanil | Zalviso</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Sufentanil torrex</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Sufenta</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Sufenta</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dzuveo | Sufentanil Actavis | Sufentanil hameln | Sufentanil Hikma | Zalviso</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Sufentanil hameln</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Zalviso</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Sufentanil hameln | Sufentanil Narco-med</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dzuveo | Zalviso</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Zalviso</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Dzuveo | Zalviso</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fentatienil | Zalviso</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Hana sufentanil | Hanlim Sufentanil | Sufental</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Sufenta</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Sufenta</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Sufenta</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Zuftil</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dzuveo | Zalviso</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dzuveo | Sufentanil hameln</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Sufenta</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dsuvia | Sufenta</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Sufentanilo | Zalviso</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Dzuveo</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Sufenta</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Sufenta</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Sufenta</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Micro sufentanil | Pharma q sufentanil | Sufenta | Sufentanil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30913200">
<a name="30913200"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 775: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2019a;133(4):e285-e286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/30913200/pubmed" id="30913200" target="_blank">30913200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 209: obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019b;133(3):e208-e225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34412076">
<a name="34412076"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Clinical Consensus–Obstetrics. Pharmacologic stepwise multimodal approach for postpartum pain management: ACOG clinical consensus no. 1. <i>Obstet Gynecol.</i> 2021;138(3):507-517. doi:10.1097/AOG.0000000000004517<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/34412076/pubmed" id="34412076" target="_blank">34412076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28742676">
<a name="28742676"></a>American College of Obstetricians and Gynecologists’ (ACOG) Committee on Clinical Consensus–Obstetrics. Committee opinion no. 711: opioid use and opioid use disorder in pregnancy. <i>Obstet Gynecol</i>. 2017;130(2):e81-e94. doi:10.1097/AOG.0000000000002235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/28742676/pubmed" id="28742676" target="_blank">28742676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1530752">
<a name="1530752"></a>Anand KJ and Hickey PR. Halothane-Morphine compared with high-dose sufentanil for anesthesia and postoperative analgesia in neonatal cardiac surgery. <i>N Engl J Med</i>. 1992;326(1):1-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/1530752/pubmed" id="1530752" target="_blank">1530752</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Barash PG, Cullen BF, Stoelting RK, Cahalan M, Stock C, eds. <i>Clinical Anesthesia</i>. 6th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17520986">
<a name="17520986"></a>Bayrak F, Gunday I, Memis D, Turan A. A comparison of oral midazolam, oral tramadol, and intranasal sufentanil premedication in pediatric patients. <i>J Opioid Manag</i>. 2007;3(2):74-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/17520986/pubmed" id="17520986" target="_blank">17520986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6238552">
<a name="6238552"></a>Bovill JG, Sebel PS, Blackburn CL, et al, “The Pharmacokinetics of Sufentanil in Surgical Patients,” <i>Anesthesiology</i>, 1984, 61(5):502-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/6238552/pubmed" id="6238552" target="_blank">6238552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2959172">
<a name="2959172"></a>Bowdle TA, “Myoclonus Following Sufentanil Without EEG Seizure Activity,” <i>Anesthesiology</i>, 1987, 67(4):593-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/2959172/pubmed" id="2959172" target="_blank">2959172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23414717">
<a name="23414717"></a>Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3)(suppl 1):S12-S18. doi: 10.1016/j.amjmed.2012.12.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/23414717/pubmed" id="23414717" target="_blank">23414717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26827847">
<a name="26827847"></a>Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. <i>J Pain</i>. 2016;17(2):131-157. doi:10.1016/j.jpain.2015.12.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/26827847/pubmed" id="26827847" target="_blank">26827847</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Coté CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 5th ed. Philadelphia, PA: Saunders Elsevier; 2013.</div>
</li>
<li>
<div class="reference">
                  Cuypers L, Wiebalck A, Vertommen JD, et al. Epidural sufentanil for postcesarean pain: breast milk levels and effects on the baby. <i>Acta Aneasthiol Belg</i>. 1995;46:104-105.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2964213">
<a name="2964213"></a>Davis PJ, Stiller RL, Cook DR, et al. Pharmacokinetics of sufentanil in adolescent patients with chronic renal failure. <i>Anesth Analg.</i> 1988;67(3):268-271.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/2964213/pubmed" id="2964213" target="_blank">2964213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31511863">
<a name="31511863"></a>de Vries F, Bruin M, Lobatto DJ, et al. Opioids and their endocrine effects: a systematic review and meta-analysis. <i>J Clin Endocrinol Metab.</i> 2020;105(3):1020-1029. doi:10.1210/clinem/dgz022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/31511863/pubmed" id="31511863" target="_blank">31511863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36327391">
<a name="36327391"></a>Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. <i>MMWR Recomm Rep.</i> 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/36327391/pubmed" id="36327391" target="_blank">36327391</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Dsuvia (sufentanil) sublingual tablet [prescribing information]. Hayward, CA: AcelRx Pharmaceuticals Inc; May 2021.</div>
</li>
<li>
<div class="reference">
                  Dsuvia (sufentanil) sublingual tablet [prescribing information]. Hayward, CA: AcelRx Pharmaceuticals Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29498947">
<a name="29498947"></a>Fisher DM, Chang P, Wada DR, Dahan A, Palmer PP. Pharmacokinetic properties of a sufentanil sublingual tablet intended to treat acute pain. <i>Anesthesiology</i>. 2018;128(5):943-952. doi: 10.1097/ALN.0000000000002145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/29498947/pubmed" id="29498947" target="_blank">29498947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35066756">
<a name="35066756"></a>Gadelha MR, Karavitaki N, Fudin J, Bettinger JJ, Raff H, Ben-Shlomo A. Opioids and pituitary function: expert opinion. <i>Pituitary</i>. 2022;25(1):52-63. doi:10.1007/s11102-021-01202-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/35066756/pubmed" id="35066756" target="_blank">35066756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7618699">
<a name="7618699"></a>Gust R and Böhrer H, “Stiff-Man Syndrome Associated With Continuous Sufentanil Administration,” <i>Anaesthesia</i>, 1995, 50(6):575.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/7618699/pubmed" id="7618699" target="_blank">7618699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2897172">
<a name="2897172"></a>Henderson JM, Brodsky DA, Fisher DM, Brett CM, Hertzka RE. Pre-induction of anesthesia in pediatric patients with nasally administered sufentanil. <i>Anesthesiology</i>. 1988;68(5):671-675.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/2897172/pubmed" id="2897172" target="_blank">2897172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28267689">
<a name="28267689"></a>Hill MV, Stucke RS, McMahon ML, Beeman JL, Barth RJ Jr. An educational intervention decreases opioid prescribing after general surgical operations. <i>Ann Surg</i>. 2018;267(3):468-472. doi:10.1097/SLA.0000000000002198<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/28267689/pubmed" id="28267689" target="_blank">28267689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24662315">
<a name="24662315"></a>Hitt JM, Corcoran T, Michienzi K, Creighton P, Heard C. An evaluation of intranasal sufentanil and dexmedetomidine for pediatric dental sedation. <i>Pharmaceutics</i>. 2014;6(1):175-184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/24662315/pubmed" id="24662315" target="_blank">24662315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22291123">
<a name="22291123"></a>Hudak ML, Tan RC; Committee on Drugs, Committee on Fetus and Newborn, American Academy of Pediatrics. Neonatal drug withdrawal. <i>Pediatrics</i>. 2012;129(2):540-560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/22291123/pubmed" id="22291123" target="_blank">22291123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34942181">
<a name="34942181"></a>Jilani SM, Jones HE, Grossman M, et al. Standardizing the clinical definition of opioid withdrawal in the neonate. <i>J Pediatr.</i> 2022;243:33-39.e1. doi:10.1016/j.jpeds.2021.12.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/34942181/pubmed" id="34942181" target="_blank">34942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7631952">
<a name="7631952"></a>Loftus JR, Hill H, Cohen SE. Placental transfer and neonatal effects of epidural sufentanil and fentanyl administered with bupivacaine during labor. <i>Anesthesiology</i>. 1995;83(2):300-308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/7631952/pubmed" id="7631952" target="_blank">7631952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20849451">
<a name="20849451"></a>Lundeberg S, Roelofse JA. Aspects of pharmacokinetics and pharmacodynamics of sufentanil in pediatric practice. <i>Pediatr Anaesth</i>. 2011;21:274-279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/20849451/pubmed" id="20849451" target="_blank">20849451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2963561">
<a name="2963561"></a>Madej TH, Strunin L. Comparison of epidural fentanyl with sufentanil. Analgesia and side effects after a single bolus dose during elective caesarean section. <i>Anaesthesia</i>. 1987;42(11):1156-1161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/2963561/pubmed" id="2963561" target="_blank">2963561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29595994">
<a name="29595994"></a>Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM Clinical Protocol #28: Peripartum analgesia and anesthesia for the breastfeeding mother. <i>Breastfeed Med.</i> 2018;13(3):164-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/29595994/pubmed" id="29595994" target="_blank">29595994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35921640">
<a name="35921640"></a>Meek JY, Noble L; Section on breastfeeding. Policy statement: breastfeeding and the use of human milk. <i>Pediatrics.</i> 2022;150(1):e2022057988. doi: 10.1542/peds.2022-057988.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/35921640/pubmed" id="35921640" target="_blank">35921640</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Miller RD. <i>Miller’s Anesthesia</i>. 7th ed. Philadelphia, PA: Churchill Livingstone; 2010.</div>
</li>
<li>
<div class="reference">
                  Miller RD. <i>Miller’s Anesthesia</i>. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3159311">
<a name="3159311"></a>Moore RA, Yang SS, McNicholas KW, Gallagher JD, Clark DL. Hemodynamic and anesthetic effects of sufentanil as the sole anesthetic for pediatric cardiovascular surgery.<i> Anesthesiology</i>. 1985;62(6):725-731.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/3159311/pubmed" id="3159311" target="_blank">3159311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12509564">
<a name="12509564"></a>Nguyen The Tich S, Vecchierini MF, Debillon T, et al. Effects of sufentanil on electroencephalogram in very and extremely preterm neonates. <i>Pediatrics</i>. 2003;111(1):123-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/12509564/pubmed" id="12509564" target="_blank">12509564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33106341">
<a name="33106341"></a>Patrick SW, Barfield WD, Poindexter BB; Committee on Fetus and Newborn, Committee on Substance Use and Prevention. Neonatal opioid withdrawal syndrome. <i>Pediatrics.</i> 2020;146(5):e2020029074. doi:10.1542/peds.2020-029074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/33106341/pubmed" id="33106341" target="_blank">33106341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15675259">
<a name="15675259"></a>Roelofse JA, Shipton EA, de la Harpe CJ, Blignaut RJ. Intranasal sufentanil/midazolam versus ketamine/midazolam for analgesia/sedation in the pediatric population prior to undergoing multiple dental extractions under general anesthesia: a prospective, double-blind, randomized comparison. <i>Anesth Prog</i>. 2004;51(4):114-121.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/15675259/pubmed" id="15675259" target="_blank">15675259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC; Committee on Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-e809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8896944">
<a name="8896944"></a>Scholz J, Steinfath M, and Schulz M, “Clinical Pharmacokinetics of Alfentanil, Fentanyl, and Sufentanil. An Update,” <i>Clin Pharmacokinet</i>, 1996, 31(4):275-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/8896944/pubmed" id="8896944" target="_blank">8896944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6119930">
<a name="6119930"></a>Sebel PS, Bovil JG. Cardiovascular effects of sufentanil anesthesia. <i>Anesth Analg</i>. 1982;61(2):115-119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/6119930/pubmed" id="6119930" target="_blank">6119930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2870669">
<a name="2870669"></a>Starr NJ, Sethna DH, Estafanous FG. Bradycardia and asystole following the rapid administration of sufentanil with vecuronium. <i>Anesthesiology</i>. 1986;64(4):521-523.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/2870669/pubmed" id="2870669" target="_blank">2870669</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sufenta (sufentanil citrate) [prescribing information]. Lake Forest, IL: Akorn Inc; December 2008.</div>
</li>
<li>
<div class="reference">
                  Sufentanil Citrate [prescribing information]. Lake Forest, IL: Akorn Inc; September 2022.</div>
</li>
<li>
<div class="reference">
                  Sufentanil Citrate injection [prescribing information]. Lake Forest, IL: Akorn Inc; December 2023.</div>
</li>
<li>
<div class="reference">
                  Sufentanil Citrate [product monograph]. Mississauga, Ontario, Canada: SteriMax Inc; June 2015.</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration (FDA). FDA drug safety communication: FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use</a>. Published April 13, 2023. Accessed April 17, 2023.</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration (FDA). FDA Drug Safety Communication. MedWatch. FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-health-care-professionals-discuss-naloxone-all-patients-when-prescribing-opioid-pain" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-health-care-professionals-discuss-naloxone-all-patients-when-prescribing-opioid-pain</a>. Published July 23, 2020. Accessed September 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24824135">
<a name="24824135"></a>Woloszczuk-Gebicka B, Grabowski T, Borucka B, Karas-Trzeciak M. Pharmacokinetics of sufentanil administered with 0.2% ropivacaine as a continuous epidural infusion for postoperative pain relief in infants. <i>Paediatr Anaesth</i>. 2014;24(9):962-967.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sufentanil-pediatric-drug-information/abstract-text/24824135/pubmed" id="24824135" target="_blank">24824135</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. https://apps.who.int/iris/handle/10665/62435. Published 2002.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12812 Version 336.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
